Equillium Inc (EQ) |
|
7.19 -0.01 (-0.14%)
|
03-03 16:59 |
|
Open: |
7.44 |
Pre. Close: |
7.2 |
|
High:
|
7.68 |
Low:
|
7.15 |
|
Volume:
|
211,873 |
Market Cap:
|
209M |
|
|
|
|
Equillium, Inc. is a biotechnology company, which engages in the development of products for severe immuno-inflammatory disorders with high unmet medical need. The company is headquartered in La Jolla, California and currently employs 16 full-time employees. The firm develops products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its initial product candidate, EQ001 (itolizumab), is a clinical-stage, monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in the modulation of effector T cells, or Teff cells. Activated Teff cells drive a number of immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. EQ001, disease modifying treatment for multiple severe immuno-inflammatory disorders. The company plans to initiate a Phase Ib/II clinical trial of EQ001 for the treatment of acute graft-versus-host disease, or aGVHD. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
7.755 - 7.799 |
7.799 - 7.847 |
|
Low:
|
7.033 - 7.079 |
7.079 - 7.129 |
|
Close:
|
7.103 - 7.183 |
7.183 - 7.27 |
|
Technical analysis |
as of: 2021-03-03 4:39:31 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 10.68 One year: 13.23 |
| Support: |
Support1: 5.61 Support2: 4.67 |
| Resistance: |
Resistance1: 9.14 Resistance2: 11.33 |
| Pivot: |
8.67  |
| Moving Average: |
MA(5): 7.30 MA(20): 8.55
MA(100): 5.93 MA(250): 5.51 |
| MACD: |
MACD(12,26): 0.16 Signal(9): 0.52 |
| Stochastic oscillator: |
%K(14,3): 8.11 %D(3): 7.84 |
| RSI: |
RSI(14): 44.80 |
| 52-week: |
High: 27.05 Low: 2.20 Change(%): 50.1 |
| Average Vol(K): |
3-Month: 74843 10-Days: 34857 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.EQ has closed above bottom band by 18.4%. Bollinger Bands are 116.4% wider than normal. The large width of the bands suggest high volatility as compared to EQ's normal range. The bands have been in this wide range for 18 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Wed, 03 Mar 2021
Equillium (NASDAQ:EQ) Earns Buy Rating from Analysts at Jonestrading - MarketBeat
Tue, 02 Mar 2021
Equillium to Present at the H.C. Wainwright Global Life Sciences Conference - GlobeNewswire
Thu, 18 Feb 2021
Equillium to Present at the SVB Leerink 10th Annual Global Healthcare Conference - Yahoo Finance
Fri, 12 Feb 2021
Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience - Yahoo Finance
Tue, 09 Feb 2021
Equillium (EQ) Receives a Rating Update from a Top Analyst - Analyst Ratings
Tue, 09 Feb 2021
Equillium Announces the Appointment of Katherine Xu to the Board of Directors - GlobeNewswire
|
Financial Analysis |
| Growth |
|
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
25 |
| Shares Float (M) |
14 |
|
% Held by Insiders
|
44.12 |
|
% Held by Institutions
|
34.21 |
|
Shares Short (K)
|
752 |
|
Shares Short P. Month (K)
|
375 |
Stock Financials |
|
EPS
|
-1.540 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
3.160 |
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-22.7 |
|
Return on Equity (ttm)
|
-44.8 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-1.139 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-25 |
|
Levered Free Cash Flow (M)
|
-16 |
Stock Valuations |
|
PE Ratio
|
-4.67 |
|
PEG Ratio
|
|
|
Price to Book value
|
2.28 |
|
Price to Sales
|
|
|
Price to Cash Flow
|
-7.00 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
